Emerging Risk Biomarkers in Cardiovascular Diseases and Disorders

Overview

Journal J Lipids

Publisher Wiley

Date 2015 May 8

PMID 25949827

Citations 115

Authors

Ravi Kant Upadhyay

Affiliations

Soon will be listed here.

Abstract

Present review article highlights various cardiovascular risk prediction biomarkers by incorporating both traditional risk factors to be used as diagnostic markers and recent technologically generated diagnostic and therapeutic markers. This paper explains traditional biomarkers such as lipid profile, glucose, and hormone level and physiological biomarkers based on measurement of levels of important biomolecules such as serum ferritin, triglyceride to HDLp (high density lipoproteins) ratio, lipophorin-cholesterol ratio, lipid-lipophorin ratio, LDL cholesterol level, HDLp and apolipoprotein levels, lipophorins and LTPs ratio, sphingolipids, Omega-3 Index, and ST2 level. In addition, immunohistochemical, oxidative stress, inflammatory, anatomical, imaging, genetic, and therapeutic biomarkers have been explained in detail with their investigational specifications. Many of these biomarkers, alone or in combination, can play important role in prediction of risks, its types, and status of morbidity. As emerging risks are found to be affiliated with minor and microlevel factors and its diagnosis at an earlier stage could find CVD, hence, there is an urgent need of new more authentic, appropriate, and reliable diagnostic and therapeutic markers to confirm disease well in time to start the clinical aid to the patients. Present review aims to discuss new emerging biomarkers that could facilitate more authentic and fast diagnosis of CVDs, HF (heart failures), and various lipid abnormalities and disorders in the future.

Citing Articles

Systematic review and meta‑analysis of factors predicting postoperative lung function after lung cancer resection.

Wang H, He L, Hu X, Xian G Wideochir Inne Tech Maloinwazyjne. 2025; 19(3):289-298.

PMID: 40041108 PMC: 11867271. DOI: 10.20452/wiitm.2024.17892.

Impact of Diabetes Mellitus on Coronary Artery Disease Severity: A Comparative Analysis of Diabetic and Non-diabetic Patients.

Arshad M, Jalal-Ud-Din M, Qayyum J, Zainab M, Shah I, Fayyaz S Cureus. 2025; 17(1):e77344.

PMID: 39949437 PMC: 11821364. DOI: 10.7759/cureus.77344.

Molecular Mechanisms of Vascular Tone in Exercising Pediatric Populations: A Comprehensive Overview on Endothelial, Antioxidative, Metabolic and Lipoprotein Signaling Molecules.

Haferanke J, Baumgartner L, Willinger L, Oberhoffer-Fritz R, Schulz T Int J Mol Sci. 2025; 26(3).

PMID: 39940797 PMC: 11817131. DOI: 10.3390/ijms26031027.

Evaluation of Biologics ACE2/Ang(1-7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies.

Daniell H, Wakade G, Nair S, Singh R, Emanuel S, Brock B Pharmaceutics. 2025; 17(1).

PMID: 39861664 PMC: 11768411. DOI: 10.3390/pharmaceutics17010012.

Prevalence of Vitamin K2 Deficiency and Its Association with Coronary Artery Disease: A Case-Control Study.

Ahmed S, Yar A, Ghaith A, Alahmadi R, Almaleki F, Alahmadi H Diseases. 2025; 13(1).

PMID: 39851476 PMC: 11764201. DOI: 10.3390/diseases13010012.

References

Naylor A . Identifying the high-risk carotid plaque. J Cardiovasc Surg (Torino). 2014; 55(2 Suppl 1):11-20. View

Al-Ghoul W, Kim M, Fazal N, Azim A, Ali A . Evidence for simvastatin anti-inflammatory actions based on quantitative analyses of NETosis and other inflammation/oxidation markers. Results Immunol. 2014; 4:14-22. PMC: 4009405. DOI: 10.1016/j.rinim.2014.03.001. View

Fitchett D, Mancini G, Gregoire J, Anderson T, McPherson R . Risk stratification and selection for statin therapy: going beyond Framingham. Can J Cardiol. 2014; 30(6):667-70. DOI: 10.1016/j.cjca.2014.03.006. View

Moylan S, Berk M, Dean O, Samuni Y, Williams L, ONeil A . Oxidative & nitrosative stress in depression: why so much stress?. Neurosci Biobehav Rev. 2014; 45:46-62. DOI: 10.1016/j.neubiorev.2014.05.007. View

Thifault E, Cormier H, Bouchard-Mercier A, Rudkowska I, Paradis A, Garneau V . Effects of age, sex, body mass index and APOE genotype on cardiovascular biomarker response to an n-3 polyunsaturated fatty acid supplementation. J Nutrigenet Nutrigenomics. 2013; 6(2):73-82. DOI: 10.1159/000350744. View

Schnabel R, Seiffert M, Wilde S, Schirmer J, Koschyk D, Conradi L . Kidney injury and mortality after transcatheter aortic valve implantation in a routine clinical cohort. Catheter Cardiovasc Interv. 2014; 85(3):440-7. DOI: 10.1002/ccd.25588. View

Torres T, Bettencourt N, Mendonca D, Vasconcelos C, Silva B, Selores M . Complement C3 as a marker of cardiometabolic risk in psoriasis. Arch Dermatol Res. 2014; 306(7):653-60. DOI: 10.1007/s00403-014-1467-5. View

Sakai J, Rawson R . The sterol regulatory element-binding protein pathway: control of lipid homeostasis through regulated intracellular transport. Curr Opin Lipidol. 2001; 12(3):261-6. DOI: 10.1097/00041433-200106000-00004. View

Raut S, Hamill M, Daniels S, Heath A . Value assignment to the WHO 3rd International Standard for Blood Coagulation Fibrinogen Plasma (09/264): communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12(10):1754-7. DOI: 10.1111/jth.12668. View

10.

Strickland D, Au D, Cunfer P, Muratoglu S . Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity. Arterioscler Thromb Vasc Biol. 2014; 34(3):487-98. PMC: 4304649. DOI: 10.1161/ATVBAHA.113.301924. View

11.

Ferroni P, Riondino S, Vazzana N, Santoro N, Guadagni F, Davi G . Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost. 2012; 108(6):1109-23. DOI: 10.1160/TH12-08-0550. View

12.

Zsiros N, Paragh G, Harangi M . [Clinical significance of and treatment options for increased lipoprotein(a)]. Orv Hetil. 2014; 155(16):607-14. DOI: 10.1556/OH.2014.29877. View

13.

Smith A, Tsuchida K, Hanneman E, Suzuki T, Wells M . Isolation, characterization, and cDNA sequence of two fatty acid-binding proteins from the midgut of Manduca sexta larvae. J Biol Chem. 1992; 267(1):380-4. View

14.

Harris W . The omega-3 index: from biomarker to risk marker to risk factor. Curr Atheroscler Rep. 2009; 11(6):411-7. DOI: 10.1007/s11883-009-0062-2. View

15.

Swede H, Hajduk A, Sharma J, Rawal S, Rasool H, Vella A . Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort. Int J Cancer. 2013; 134(8):1862-70. DOI: 10.1002/ijc.28504. View

16.

Yadav S, Singh M, Dwivedi P, Mandal R, Usman K, Khattri S . Significance of impaired serum gelatinases activities in metabolic syndrome. Toxicol Int. 2014; 21(1):107-11. PMC: 3989907. DOI: 10.4103/0971-6580.128818. View

17.

McMahon M, Skaggs B . Pathogenesis and treatment of atherosclerosis in lupus. Rheum Dis Clin North Am. 2014; 40(3):475-95, viii. PMC: 6152881. DOI: 10.1016/j.rdc.2014.04.003. View

18.

Esposito E, Cordaro M, Cuzzocrea S . Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury. Pharmacol Res. 2014; 86:26-31. DOI: 10.1016/j.phrs.2014.05.009. View

19.

Paltsev A, Myakotnykh V, Torgashov M . [Blood lipid parameters in combat veterans with posttraumatic stress disorders]. Ter Arkh. 2014; 86(2):56-62. View

20.

Yayan J . Emerging families of biomarkers for coronary artery disease: inflammatory mediators. Vasc Health Risk Manag. 2013; 9:435-56. PMC: 3751465. DOI: 10.2147/VHRM.S45704. View